Arovella Therapeutics Ltd (ALA)

Currency in AUD
0.100
0.000(0.00%)
Closed·
ALA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ALA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1000.100
52 wk Range
0.0680.210
Key Statistics
Bid/Ask
0.105 / 0.10
Prev. Close
0.1
Open
0.1
Day's Range
0.1-0.1
52 wk Range
0.068-0.21
Volume
47.63K
Average Volume (3m)
1.8M
1-Year Change
-28.57%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Arovella Therapeutics Ltd Company Profile

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Arovella Therapeutics Ltd Earnings Call Summary for Q3/2025

  • Arovella reports $23.5M cash position, bolstered by $15M placement, ensuring funding for LL-101 phase one trials in 2025
  • Company aims to file IND for LL-101 by Q2 2024, focusing on innovative iNKT cell therapies for various cancers
  • Analyst consensus target of $0.21, with revenue forecasts of $2.12M for FY2025 and $2.45M for FY2026
  • CEO emphasizes unique position in iNKT cell therapies and data-driven approach to anti-cancer research
  • Potential risks include regulatory hurdles, evolving competitive landscape, and critical need for successful clinical trials
Last Updated: 29/04/2025, 03:02
Read Full Transcript

Compare ALA to Peers and Sector

Metrics to compare
ALA
Peers
Sector
Relationship
P/E Ratio
−19.0x−6.1x−0.5x
PEG Ratio
−0.38−0.010.00
Price/Book
10.3x1.8x2.6x
Price / LTM Sales
34.5x9.8x3.3x
Upside (Analyst Target)
230.0%186.7%42.8%
Fair Value Upside
Unlock15.8%6.5%Unlock

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
-- / --
Revenue / Forecast
3.44M / --
EPS Revisions
Last 90 days

ALA Income Statement

FAQ

What Stock Exchange Does Arovella Therapeutics Trade On?

Arovella Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Arovella Therapeutics?

The stock symbol for Arovella Therapeutics is "ALA."

What Is the Arovella Therapeutics Market Cap?

As of today, Arovella Therapeutics market cap is 118.95M.

What Is Arovella Therapeutics's Earnings Per Share (TTM)?

The Arovella Therapeutics EPS (TTM) is -0.01.

From a Technical Analysis Perspective, Is ALA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Arovella Therapeutics Stock Split?

Arovella Therapeutics has split 5 times.

How Many Employees Does Arovella Therapeutics Have?

Arovella Therapeutics has 27 employees.

What is the current trading status of Arovella Therapeutics (ALA)?

As of 06 Aug 2025, Arovella Therapeutics (ALA) is trading at a price of 0.10, with a previous close of 0.10. The stock has fluctuated within a day range of 0.10 to 0.10, while its 52-week range spans from 0.07 to 0.21.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.